GeNeuro Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 19

Employees

  • Stock Symbol
  • GNRO

Stock Symbol

  • Share Price
  • $0.15
  • (As of Friday Closing)

GeNeuro General Information

Description

GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

Contact Information

Website
www.geneuro.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 3, Chemin du Pré-Fleuri
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Corporate Office
  • 3, Chemin du Pré-Fleuri
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022

GeNeuro Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeNeuro Stock Performance

As of 14-Feb-2025, GeNeuro’s stock price is $0.15. Its current market cap is $4.33M with 29.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.15 $0.13 $0.04 - $2.56 $4.33M 29.6M 450K -$0.64

GeNeuro Financials Summary

As of 31-Dec-2023, GeNeuro has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 35,875 35,875 33,408 87,204
Revenue 0 0 0 0
EBITDA (15,728) (15,728) (12,529) (7,708)
Net Income (15,968) (15,968) (12,827) (8,061)
Total Assets 7,032 7,032 12,301 14,198
Total Debt 14,776 14,776 7,486 4,246
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeNeuro Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving th
Drug Discovery
Geneva, Switzerland
19 As of 2023

Zug, Switzerland
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GeNeuro Competitors (50)

One of GeNeuro’s 50 competitors is CRISPR Therapeutics, a Formerly VC-backed company based in Zug, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Senti Bio Formerly VC-backed South San Francisco, CA
Alzheon Venture Capital-Backed Framingham, MA
Quince Therapeutics Formerly VC-backed South San Francisco, CA
Alzinova Corporation Gothenburg, Sweden
You’re viewing 5 of 50 competitors. Get the full list »

GeNeuro Patents

GeNeuro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3185024-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020
EP-4157871-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020
EP-3916015-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Inactive 28-May-2020
AU-2021281054-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020
US-20240301040-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020 C07K16/1036
To view GeNeuro’s complete patent history, request access »

GeNeuro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeNeuro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view GeNeuro’s complete esg history, request access »

GeNeuro FAQs

  • When was GeNeuro founded?

    GeNeuro was founded in 2006.

  • Where is GeNeuro headquartered?

    GeNeuro is headquartered in Geneva, Switzerland.

  • What is the size of GeNeuro?

    GeNeuro has 19 total employees.

  • What industry is GeNeuro in?

    GeNeuro’s primary industry is Drug Discovery.

  • Is GeNeuro a private or public company?

    GeNeuro is a Public company.

  • What is GeNeuro’s stock symbol?

    The ticker symbol for GeNeuro is GNRO.

  • What is the current stock price of GeNeuro?

    As of 14-Feb-2025 the stock price of GeNeuro is $0.15.

  • What is the current market cap of GeNeuro?

    The current market capitalization of GeNeuro is $4.33M.

  • Who are GeNeuro’s competitors?

    CRISPR Therapeutics, Senti Bio, Alzheon, Quince Therapeutics, and Alzinova are some of the 50 competitors of GeNeuro.

  • What is GeNeuro’s annual earnings per share (EPS)?

    GeNeuro’s EPS for 12 months was -$0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »